Document is current

Article History

Accepted: 8 November 2024

First Online: 3 February 2025

Competing interests

: C.A. holds patents and provisional patent applications in the field of engineered T cell therapies. C.A. receives licensing fees and royalties from Immatics (through previous institution Baylor College of Medicine), participated in advisory boards for Kite/Gilead, Janssen and Celgene/BMS, and received sponsored travel from Gilead (through current institution Lausanne University Hospital (CHUV)). G.C. has received honoraria from Bristol Myers Squibb. CHUV has received honoraria for advisory services provided by G.C. to Iovance and EVIR. G.C. has received royalties from the University of Pennsylvania for CAR-T cell therapy licensed to Novartis and Tmunity Therapeutics. G.C. has received royalties from the Ludwig Institute for Cancer Research, UNIL and CHUV for NeoTIL intellectual property previously licensed to Tigen Pharma. G.C. is the inventor in technologies related to T cell expansion and engineering for T cell therapy. A.M. is a clinical adviser for Immatics.